Comment

. 2023 Jun;23(6):639-640.

doi: 10.1016/S1473-3099(23)00056-7. Epub 2023 Feb 10.

Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants

Carlos K H Wong¹, Kristy T K Lau², Gabriel M Leung³

Affiliations

¹ Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China. Electronic address: carlosho@hku.hk.
² Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
³ WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China.

PMID: 36780911
PMCID: PMC9917404
DOI: 10.1016/S1473-3099(23)00056-7

Comment

Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants

Carlos K H Wong et al. Lancet Infect Dis. 2023 Jun.

. 2023 Jun;23(6):639-640.

doi: 10.1016/S1473-3099(23)00056-7. Epub 2023 Feb 10.

Authors

Carlos K H Wong¹, Kristy T K Lau², Gabriel M Leung³

Affiliations

¹ Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China. Electronic address: carlosho@hku.hk.
² Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
³ WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China.

PMID: 36780911
PMCID: PMC9917404
DOI: 10.1016/S1473-3099(23)00056-7

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Figures

See this image and copyright information in PMC

Comment on

Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Aggarwal NR, et al. Lancet Infect Dis. 2023 Jun;23(6):696-705. doi: 10.1016/S1473-3099(23)00011-7. Epub 2023 Feb 10. Lancet Infect Dis. 2023. PMID: 36780912 Free PMC article.

Cited by

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.
Low EV, Pathmanathan MD, Ten YY, Chidambaram SK, Kim WR, Lee WJ, Teh ZW, Appannan MR, Ismail M, Samad AA, Peariasamy KM. Low EV, et al. BMC Infect Dis. 2024 Aug 5;24(1):780. doi: 10.1186/s12879-024-09679-1. BMC Infect Dis. 2024. PMID: 39103829 Free PMC article.
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies.
Souza KM, Carrasco G, Rojas-Cortés R, Michel Barbosa M, Bambirra EHF, Castro JL, Alvares-Teodoro J. Souza KM, et al. PLoS One. 2023 Oct 12;18(10):e0284006. doi: 10.1371/journal.pone.0284006. eCollection 2023. PLoS One. 2023. PMID: 37824507 Free PMC article.
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.
Aggarwal NR, Beaty LE, Bennett TD, Fish LE, Jacobs JR, Mayer DA, Molina KC, Peers JL, Richardson DB, Russell S, Varela A, Webb BJ, Wynia MK, Xiao M, Carlson NE, Ginde AA. Aggarwal NR, et al. Lancet Reg Health Am. 2024 Feb 9;31:100693. doi: 10.1016/j.lana.2024.100693. eCollection 2024 Mar. Lancet Reg Health Am. 2024. PMID: 38500962 Free PMC article.

References

1. Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(23)00011-7. published online Feb 10. - DOI - PMC - PubMed
1. Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (paxlovid) for COVID-19: a rapid review and meta-analysis. J Med Virol. 2022;95 - PMC - PubMed
1. Cheema HA, Jafar U, Sohail A, et al. Nirmatrelvir–ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2023;95 - PubMed
1. Zheng Q, Ma P, Wang M, et al. Efficacy and safety of paxlovid for COVID-19: a meta-analysis. J Infect. 2023;86:66–117. - PMC - PubMed
1. Schwartz KL, Wang J, Tadrous M, et al. Real-world effectiveness of nirmatrelvir/ritonavir use for COVID-19: a population-based cohort study in Ontario, Canada. medRxiv. 2022 doi: 10.1101/2022.11.03.22281881. published online Nov 5. (preprint). - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants

Affiliations

Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary concepts

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous